Celyad SA - Asset Resilience Ratio
Celyad SA (CYAD) has an Asset Resilience Ratio of 0.00% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2022)
This chart shows how Celyad SA's Asset Resilience Ratio has changed over time. Check Celyad SA (CYAD) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Celyad SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CYAD stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Celyad SA maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Celyad SA Industry Peers by Asset Resilience Ratio
Compare Celyad SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Celyad SA (2013–2022)
The table below shows the annual Asset Resilience Ratio data for Celyad SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.00% | €0.00 ≈ $0.00 |
€19.72 Million ≈ $23.05 Million |
-- |
| 2021-12-31 | 0.00% | €0.00 ≈ $0.00 |
€79.94 Million ≈ $93.46 Million |
-- |
| 2020-12-31 | 0.00% | €0.00 ≈ $0.00 |
€66.08 Million ≈ $77.26 Million |
-- |
| 2019-12-31 | 0.00% | €0.00 ≈ $0.00 |
€89.84 Million ≈ $105.03 Million |
-- |
| 2018-12-31 | 9.75% | €9.20 Million ≈ $10.75 Million |
€94.30 Million ≈ $110.25 Million |
-3.97pp |
| 2017-12-31 | 13.72% | €10.65 Million ≈ $12.45 Million |
€77.63 Million ≈ $90.75 Million |
-10.94pp |
| 2016-12-31 | 24.66% | €34.23 Million ≈ $40.02 Million |
€138.81 Million ≈ $162.28 Million |
+20.06pp |
| 2015-12-31 | 4.60% | €7.34 Million ≈ $8.58 Million |
€159.53 Million ≈ $186.50 Million |
-1.47pp |
| 2014-12-31 | 6.07% | €2.67 Million ≈ $3.12 Million |
€43.98 Million ≈ $51.41 Million |
-3.19pp |
| 2013-12-31 | 9.26% | €3.00 Million ≈ $3.51 Million |
€32.39 Million ≈ $37.86 Million |
-- |
About Celyad SA
Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding … Read more